GlassScriptPhysician profile
Mika Sachs
NPI 1790151264
$8,300.76
in general payments reported to CMS, 2019-2025
28 companies · $1,886 in 2025
The $1,886 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,210 · 2022: $1,468 · 2023: $1,515 · 2024: $2,222 · 2025: $1,886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,318 · Education: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,318.26 |
| Education | $305.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,388.32 | 2021-2025 | |
| Abbvie INC. | $939.02 | 2021-2025 | |
| Janssen Biotech, INC. | $873.72 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $598.23 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $478.86 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $433.90 | 2021-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $388.50 | 2021-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $381.86 | 2021-2025 | Winlevi, Ilumya |
| Lilly USA, LLC | $365.43 | 2021-2024 | Olumiant, Taltz, Ebglyss |
| Amgen INC. | $334.10 | 2021-2025 | Otezla, Otezla |
| Incyte Corporation | $322.25 | 2021-2025 | Opzelura |
| Dermavant Sciences, INC. | $290.33 | 2023-2024 | Vtama |
| Pfizer INC. | $288.25 | 2021-2025 | |
| Ucb, INC. | $281.37 | 2021-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $165.59 | 2021-2025 | Cabtreo, Arazlo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $129.68 | 2024-2025 | Nemluvio, Aklief, Oracea |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.96 | 2023-2025 | Spevigo |
| Organon LLC | $75.37 | 2025 | |
| Sanofi-Aventis U.S. LLC | $64.95 | 2021 | |
| Arcutis Biotherapeutics, INC. | $60.54 | 2023-2025 | Zoryve |
| Journey Medical Corporation | $59.79 | 2023-2024 | |
| Botanix Sb INC | $58.52 | 2025 | Sofdra |
| Biofrontera INC. | $55.07 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $54.59 | 2021-2023 | |
| Vyne Pharmaceuticals INC. | $38.68 | 2021 | |
| Epi Health, LLC | $35.47 | 2021 | |
| Mallinckrodt Hospital Products INC. | $28.49 | 2025 | Acthar |
| Almirall LLC | $17.92 | 2025 | Seysara, Klisyri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mika Sachs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.